Evaluating off-label uses of acetazolamide.

Area of Science:

• Pharmacology
• Nephrology
• Neurology

Background:

• Acetazolamide is a carbonic anhydrase inhibitor with established uses in epilepsy, glaucoma, edema, and altitude sickness.
• Its mechanism involves inhibiting hydrogen ion secretion in renal tubules, leading to diuresis and urinary alkalization.
• It also reduces cerebrospinal fluid and aqueous humor production, lowering intracranial and intraocular pressure.

Purpose of the Study:

• To review the current off-label uses of acetazolamide in hospitalized patients.
• To explore the potential benefits of acetazolamide in various clinical scenarios.
• To highlight the need for further research on patient selection for off-label acetazolamide therapy.

Main Methods:

• Literature review of off-label acetazolamide applications in hospitalized patients.
• Analysis of acetazolamide's pharmacological properties and mechanisms of action.
• Synthesis of evidence regarding its efficacy and safety in non-traditional indications.

Main Results:

• Acetazolamide may facilitate ventilator weaning in chronic obstructive pulmonary disease patients.
• It can help avoid invasive procedures for elevated intracranial pressure or cerebrospinal fluid leaks.
• Potential benefits include preventing high-dose methotrexate toxicity and contrast-induced nephropathy.

Conclusions:

• Acetazolamide presents potential benefits for off-label use in hospitalized patients.
• Further investigation is required to determine optimal patient selection criteria.
• Understanding these off-label uses can guide clinical practice and future research.